<DOC>
	<DOCNO>NCT02925000</DOCNO>
	<brief_summary>This phase I/IIa , Open label , Dose-escalation Study Investigating Safety , Tolerability , Pharmacokinetics Intravenous Liposomal Vinorelbine Tartrate Injection Patients Advanced Malignancy .</brief_summary>
	<brief_title>Dose-escalation Study Intravenous Liposomal Vinorelbine Tartrate Injection Patients With Advanced Malignancy</brief_title>
	<detailed_description>Protocol No : TLC178A1001 Name Finished Product : LipoVNB ( Liposomal Vinorelbine Tartrate ) Title Study : Phase I/IIa , Open label , Dose-escalation Study Investigating Safety , Tolerability , Pharmacokinetics Intravenous Liposomal Vinorelbine Tartrate Injection Patients Advanced Malignancy . Study duration : Every patient treatment period 4-week cycle completion 6 cycle , progression disease intolerance , withdrawal consent Investigator 's judgment , whichever occur first .</detailed_description>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Male female , ≥18 year age ( ≥20 year age Taiwan ) 2 . Patients histologically/cytologically confirm solid tumor , lymphoma . For expansion cohort , patient peripheral/cutaneous T cell lymphoma , Hodgkin 's lymphoma , nonHodgkin 's lymphoma would consider eligible 3 . Malignancies standard therapy , previously treat locally advanced , refractory/relapsed metastatic disease local curative surgery , curable radiotherapy , satisfactory systemic anticancer therapy longer available 4 . Assessable disease status define Cheson ( lymphoma ) modify severity weight assessment tool ( mSWAT ) ( mycosis fungoides [ MF ] Sezary syndrome [ SS ] ) criterion , measurable tumor define Response Evaluation Criteria Solid Tumors guideline ( RECIST 1.1 ) ( solid tumor ) 5 . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤2 6 . Anticipated life expectancy 3 month per Investigator 's judgement 7 . Women childbearing potential must negative urine pregnancy test screen visit 8 . Male patient female partner childbearing potential , female patient childbearing potential must agree use effective birth control . Effective birth control cessation lactation must comply least 2 week prior first study drug administration , trial participation , 3 month last dose study drug 9 . Willing able comply study procedure sign write informed consent 1 . Patient untreated inadequate control brain metastasis . Brain metastases lymphoma CNS involvement previously treat radiotherapy modality stable least 3 month prior screen without requirement corticosteroid anticonvulsant permit 2 . Prior systemic standard investigational anticancer therapy , include target therapy , chemotherapy , immunotherapy within 28 day prior first dose study drug . The mentioned condition Investigator considers drug effect , ≥5 halflives permit 3 . More 5 line previous cytotoxic therapy . For patient CTCL fail romidepsin , 4 line previous therapy 4 . Extensive prior radiotherapy 30 % bone marrow reserve prior bone marrow/stem cell transplantation within 2 year screen . Limited field radiation ≤2 week prior screen period permit 5 . Any toxicity due prior therapy resolve less Grade 2 severity Common Terminology Criteria Adverse Events ( CTCAE , Version 4.03 high ) criterion 6 . Medical history uncontrolled clinically significant abnormal cardiac conduction abnormality electrocardiogram ( ECG ) , history evidence long QT syndrome QTcF interval &gt; 450 msec male ≥470 msec female ( accord Fridericia 's correction ) screen 7 . Poor vital organ function define : Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 , pretransfusion platelet &lt; 100,000/mm3 , pretransfusion hemoglobin &lt; 9.0 mg/dL ( patient require least 2 week free blood transfusion , GCSF erythropoietin use prior hematology test ) International Normalized Ratio ( INR ) coagulation upper normal range Total bilirubin &gt; 1.5 time upper limit normal ( ULN ) Aspartate amino transferase ( AST ) Alanine amino transferase ( ALT ) &gt; 3 time ULN patient without liver metastasis liver cirrhosis Child Pugh B C stage liver disease Creatinine clearance ( Cockcroft Gault formula ) &lt; 40 mL/min 8 . Use potent inhibitor inducer cytochrome P450 enzyme CYP3A4 within 14 day prior first study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Advanced Malignancy</keyword>
	<keyword>lymphoma</keyword>
	<keyword>TLC178</keyword>
</DOC>